Journal of Clinical Oncology · 2005 · 214 citations · 21 references
MedicineImmunologyOncologyImmunizationImmunotherapyVaccinologyCancer ImmunotherapyCancer VaccinesImmunotherapy For Breast CancerTherapeutic VaccinesVaccinationVaccine-based ImmunotherapyCancer Vaccine T-cell ResponsesCd8 Positive T CellsClonal ExpansionClonal Expansion Of LymphocytesDelayed Hypersensitivity ReactionsT Cell Clonal ExpansionTumor Antigen VaccinesTumor-associated Antigen Vaccines
PURPOSE: E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 + granulocyte-macrophage colony-stimulating factor vaccine to assess safety, immunologic response, and the prevention of clinical recurrences in patients with disease-free, node-positive breast cancer (NPBC). PATIENTS AND METHODS: Fifty-three patients with NPBC were enrolled and HLA typed. HLA-A2+ patients (n = 24) were vaccinated, and HLA-A2- patients (n = 29) are observed prospectively as clinical controls. Local/systemic toxicities, immunologic responses, and time to recurrence are being measured. RESULTS: Only minor toxicities have occurred (one grade 3 [4%]). All patients have demonstrated clonal expansion of E75-specific CD8+T cells that lysed HER2/neu-expressing tumor cells. An optimal dosage and schedule have been established. Patients have developed delayed-type hypersensitivity reactions to E75 postvaccination compared with controls (33 v 7 mm; P < .01). HLA-A2+ patients have been found to have larger, more poorly differentiated, and more hormonally insensitive tumors compared to HLA-A2- patients. Despite this, the only two deaths have occurred in the control group. The disease-free survival in the vaccinated group is 85.7% compared to 59.8% in the controls at 22 months' median follow-up with a recurrence rate of 8% compared to 21%, respectively (P < .19). Median time to recurrence in the vaccinated patients was prolonged (11 v 8 months), and recurrence correlated with a weak delayed-type hypersensitivity response. CONCLUSION: This HER2/neu (E75) vaccine is safe and effective in eliciting a peptide-specific immune response in vivo. Induced HER2/neu immunity seems to reduce the recurrence rate in patients with NPBC.
21
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Marie Overgaard, Maj‐Britt Jensen, Jens Overgaard et al. · The Lancet · 1999 · 1.6K citations
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler et al. · New England Journal of Medicine · 2002 · 1.6K citations · Full text
Bernard Fisher, John Bryant, James J. Dignam et al. · Journal of Clinical Oncology · 2002 · 696 citations